All News

The approval is supported by data from the phase 3 PSMAddition trial.

Joshua Lang, MD, MS discusses how emerging biomarkers may help personalize treatment decisions while highlighting barriers to precision oncology in prostate cancer.

A reference on the key recommendations from the AUA Testosterone Deficiency guideline.

AI in medicine is here. What happens next matters for the future of health care delivery.

A 10-year registry analysis found focal HIFU and cryotherapy achieved durable cancer control and low prostate cancer mortality in localized disease.

In this episode, Gabe Canales reflects on his journey receiving a diagnosis of prostate cancer at a young age and emphasizes the importance of patient advocacy.

Matthew D. Galsky, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab for MIBC is moving the field beyond cisplatin eligibility and influencing future approaches to surgery and response-guided therapy.

Adanma Ayanambakkam, MD, MS, highlights data from the phase 1 FIT-001 trial evaluating darlifarnib plus cabozantinib in patients with advanced renal cell carcinoma.

This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.

Experts discuss why accurately recognizing CIS in patients with suspected NMIBC is essential to preventing disease progression, guiding surveillance, and expanding treatment and clinical trial opportunities.

Darlifarnib plus cabozantinib demonstrated encouraging antitumor activity with a manageable safety profile in patients with ccRCC, including both cabozantinib-naive and cabozantinib-exposed populations.

Joshua Halpern, MD, MS, reviews evidence supporting the accuracy of mail-in semen analysis and identifies patients who may benefit most from at-home testing.

CAPTAIN trial data showed TULSA preserved penile length, continence, and erectile function compared with robotic prostatectomy in localized prostate cancer.

In this episode, Jason Hafron, MD, explains how data-driven pathways and patient follow-up systems can improve quality and outcomes in urologic oncology.

Can Aydogdu, MD, highlights a study examining the utility of pre-surgical tumor-informed ctDNA to predict pathologic nodal status at radical cystectomy.

The PDUFA target action date is in the fourth quarter of 2026.

The study showed that perioperative EV–pembrolizumab improved EFS, OS, and pCR rate vs neoadjuvant cisplatin-gemcitabine in patients with MIBC who are eligible for cisplatin-based chemotherapy.

Experts discuss practical strategies to improve the detection of CIS through closer urologist-pathologist collaboration, optimized biopsy techniques, and complementary diagnostic tools.

Olaparib's indications in the US include use as a single agent for patients with HRR gene-mutated mCRPC and in combination with abiraterone and prednisone for patients with BRCA-mutated mCRPC.

These results provided the basis for the ongoing randomized phase 3 ProstACT Global trial evaluating 177Lu-rosopatamab tetraxetan in mCRPC.

Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol, discusses the clinical significance of the phase 3 PROTEUS trial and addresses concerns about the study's use of ADT in the control arm.

Amy Pearlman, MD, and Larry I. Lipshultz, MD, speak with Shane Kronstedt, MD, about research on the long-term reproductive and urologic effects of military exposures and how these findings may help improve care for veterans.

Experts discuss why CIS is frequently underrecognized, highlighting the subtle clinical and cystoscopic features of the disease and the importance of integrating multiple factors to improve detection.

This marks the first phase 3 study of a targeted radiopharmaceutical therapy in clear cell renal cell carcinoma.

Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG-naive NMIBC.

Results from a first-in-human phase 0 feasibility trial showed that combined bladder and kidney transplantation was technically feasible.

Kathryn H. Gessner, MD, PhD, discusses the current limitations in identifying appropriate candidates for bladder-preserving trimodal therapy, the promise of utDNA, and why shared decision-making remains essential.

A secondary analysis of the ASPIRE trial found residual stone volume—not conventional stone-free status, baseline volume, or density—is the strongest predictor of postureteroscopy health care utilization, with each 100-mm³ increase doubling event odds.